Cerebral Cavernous Malformation
8
0
1
4
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 74/100
25.0%
2 terminated out of 8 trials
66.7%
-19.8% vs benchmark
0%
0 trials in Phase 3/4
50%
2 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (8)
Atorvastatin Treatment of Cavernous Angiomas With Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial
Biomarkers of CASH
The Symptomatic Cerebral Cavernous Malformation Trial of REC-994
Functional Magnetic Resonance Imaging (fMRI) Vascular Reactivity in Cerebral Cavernous Malformations (CCM)
CASH (Cavernous Angiomas With Symptomatic Hemorrhage) Trial Readiness
CCM Blood Biomarker Validation Study
CoHOrt of Cerebral CavernOus maLformATion: multicEnter Prospective Observational Study
Treat_CCM: Propranolol in Familial Cerebral Cavernous Malformation